RxDoctor Payments Data

Stephen Piacentine, MD

Cardiovascular Disease · Schenectady, NYNPI 1366515595

Payments from drug & device makers

$1,786in general payments, 2019–2025

Across 97 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$531
  • Abbott$185
  • Boehringer Ingelheim$181
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$175
  • Amgen$128
  • AstraZeneca$100
  • plus $486 from 11 others

What the payments were for

  • Food & beverage$1,786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,786 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$168,281
Medicare patients
639
Services billed
2,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban645$831,796
EntrestoSacubitril/Valsartan99$149,339
XareltoRivaroxaban61$76,927
Repatha SureclickEvolocumab75$58,731
FarxigaDapagliflozin Propanediol36$42,428
Praluent PenAlirocumab59$36,030
BrilintaTicagrelor39$34,358
JardianceEmpagliflozin17$22,770
Atorvastatin Calcium861$12,065
OzempicSemaglutide12$11,104
Metoprolol Succinate553$8,974
Ranolazine ErRanolazine30$4,688
Eplerenone57$4,316
Rosuvastatin Calcium216$4,093
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$2,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$831,796645 claims
NovartisEntresto$531$149,33999 claims
Johnson & JohnsonXarelto$98$76,92761 claims
AstraZenecaFarxiga, Brilinta$100$76,78575 claims
Boehringer IngelheimJardiance$181$22,77017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →